Unmet Needs and the Future of AML Treatment

In a real-world population of patients with relapsed or refractory B-cell acute lymphoblastic leukemia, modest efficacy was demonstrated with brexucabtagene autoleucel.

Phase 2 FELIX study results show 21.3% of the 94 patients infused with obecatagene autoleucel achieved a complete response or complete response with incomplete count recovery.

In the third article of this series, Bradley McGregor, MD, gives comprehensive insights on treating patients with advanced renal cell carcinoma, with a focus on treatment sequencing.

In the third article of this series, Chung-Han Lee, MD, PhD, gives an overview of non-clear cell renal cell carcinoma, discusses key clinical trial data, and looks to the future of renal cell carcinoma treatment.

In the second article of this series, Chandler H. Park, MD, a genitourinary oncologist at Norton Cancer Institute, reviews recently updated data on advanced renal cell carcinoma treatments.

The injectable formulation of nelarabine has been granted FDA approval to treatment 2 hematologic malignancies.